ライフサイエンスコーパス: lepromatous

1 ulate in the lesions of individuals with the lepromatous (also known as disseminated) form of human l

2 indicate that macrophages from patients with lepromatous and tuberculoid leprosy and from normal dono

3 ymorphism are associated, respectively, with lepromatous and tuberculoid leprosy.

4 h robust production of Th1-type cytokines to lepromatous disease, characterized by elevated levels of

5 rm (T-lep) as compared with the disseminated lepromatous form (L-lep) of the disease.

6 of patients with the clinically progressive lepromatous form of leprosy; in contrast, galectin-3 was

7 In contrast, lesions from patients with the lepromatous form of the disease who lack effective cell-

8 uberculoid as compared with the disseminated lepromatous form of the disease.

9 increased in the lesions of the progressive, lepromatous form vs the self-limited, tuberculoid form o

10 Peripheral blood T cell responses in the lepromatous form were strongly regulated by CD28 during

11 onocytes in individuals with the progressive lepromatous form, except during reversal reactions in wh

12 Analogous to the tuberculoid and lepromatous forms of leprosy, CD may have two clinical m

13 nse occurring in the microenvironment of the lepromatous granuloma.

14 atients compared with the highly susceptible lepromatous group.

15 in the lesions of subjects with progressive lepromatous (L-lep) versus the self-limited tuberculoid

16 in Winchester, UK, showing skeletal signs of lepromatous leprosy (LL) have been studied using a multi

17 alterations were most frequently observed in lepromatous leprosy (LL) patients.

18 tured human pathogen associated with diffuse lepromatous leprosy and a reactional state known as Luci

19 eprosum (ENL), which occurs in patients with lepromatous leprosy and is characterized by neutrophil i

20 oor cellular immune response associated with lepromatous leprosy and may have important implications

21 Patients with lepromatous leprosy are unresponsive to lepromin skin-te

22 The lepromatous leprosy granuloma is a dynamic entity requir

23 ymorphonuclear leukocytes from patients with lepromatous leprosy iodinate ingested bacteria normally.

24 The chronic course of lepromatous leprosy may be interrupted by acute inflamma

25 ytes from the blood of either tuberculoid or lepromatous leprosy patients.

26 immune defect leading to the development of lepromatous leprosy resides in the lymphocyte or in the

27 in skin lesions of patients with progressive lepromatous leprosy, correlating and colocalizing with I

28 0-CD40L interaction, which is not evident in lepromatous leprosy, probably participates in the cell-m

29 The striking finding was that in lepromatous leprosy, T cells did not efficiently recogni

30 Multibacillary disease is similar to human lepromatous leprosy, with variable/high levels of antibo

31 d human polymorphism that is associated with lepromatous leprosy.

32 tana Roo, Mexico, was diagnosed with diffuse lepromatous leprosy.

33 reported almost exclusively in patients with lepromatous leprosy.

34 ability of M. leprae residing in Mphi in the lepromatous lesion.

35 suggested that the absence of expression in lepromatous lesions was most likely due to local factors

36 4+CD28+ or CD4+CD28-, and T cell clones from lepromatous lesions were predominantly CD8+CD28-.

37 urthermore, IL-10, a cytokine predominant in lepromatous lesions, blocked the IFN-gamma up-regulation

38 In tuberculoid lepromatous lesions, DC-SIGN+ cells were positive for ma

39 pressed in tuberculoid lesions compared with lepromatous lesions.

40 pression was similar in both tuberculoid and lepromatous lesions.

41 ly expressed in disseminated and progressive lepromatous lesions.

42 have recently been recognized as a model of lepromatous neuritis; the major site of early accumulati

43 Interestingly, IL-12Rbeta2 in lepromatous patients could be up-regulated by stimulatio

44 ere significantly up-regulated in lesions of lepromatous patients suffering from the disseminated for

45 leprae-induced IL-12 production by PBMC from lepromatous patients was not dependent on CD40L-CD40 lig

46 ant tuberculoid as compared with susceptible lepromatous patients, and, in vitro, monocytes produced

47 sion in ENL when compared with nonreactional lepromatous patients, both locally in the skin lesions a

48 e responsive to IL-12; however, T cells from lepromatous patients, the susceptible form of leprosy, d

49 nsiveness against mycobacterial lipid Ags in lepromatous patients, we used T cell clones to probe the

50 d IFN-gamma in tuberculoid patients, but not lepromatous patients, while IL-4 production was not indu

51 , who are able to restrict the pathogen, and lepromatous patients, who have disseminated infection.

52 was more strongly expressed in lesions from lepromatous patients, who manifest specific T cell anerg

53 cobacterium leprae in tuberculoid but not in lepromatous patients.

54 ivated T cells from tuberculoid but not from lepromatous patients.

55 ts than in with unresponsive and susceptible lepromatous patients.

56 (Lophocebus aterrimus) were inoculated with lepromatous tissue that had been serially passaged in fo

57 Using test samples isolated from lepromatous tissue, we also evaluated amplification fide

58 SIVsm) by day 30 postinoculation (p.i.) with lepromatous tissue.